Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 3/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15129281 | 1.00 | CNR2 (0.54) | CNR2XDHPTGER1CDK2CCNA2 | |
| SCHEMBL15129249 | 0.99 | CNR2 (0.52) | CNR2XDHPTGER1CDK2CCNA2 | |
| SCHEMBL15128977 | 0.88 | CNR2 (0.47) | CNR2XDH | |
| SCHEMBL15129239 | 0.82 | FFAR4 (0.42) | CNR2FFAR4 | |
| SCHEMBL15129314 | 0.82 | FFAR4 (0.42) | CNR2FFAR4 | |
| SCHEMBL12420758 | 0.82 | CNR2 (0.60) | CNR2XDHPTGER1CDK2CCNA2 | |
| SCHEMBL15129152 | 0.82 | CNR2 (0.46) | CNR2 | |
| SCHEMBL15129240 | 0.81 | XDH (0.45) | CNR2XDHCDK2CCNA2CCNA1 | |
| SCHEMBL15134602 | 0.80 | CNR2 (0.58) | CNR2PTGER1CDK2CCNA2CCNA1 | |
| SCHEMBL15129049 | 0.79 | GRIN2B (0.49) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013109991-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | CLN6, ALDH1A2, PDE6D | CNR2 1376/4885XDH 78/4885PTGER1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.